From Astrophysics to Oncology: How Paul Jaminet Is Redefining Cancer Treatment Through Science and Faith in Discovery
What if a cancer drug could hitch a ride straight into a tumor cell’s nucleus—killing malignant cells while leaving healthy tissue untouched?
That question drives Paul Jaminet, founder and president of Angiex, a biotech company pioneering a first-of-its-kind therapy known as AGX-101, a nuclear-delivered antibody drug conjugate (ADC) that targets solid tumors at their core.
In his conversation with Industry Ignited host Dr. Leeanne Aguilar, Paul shares how a journey that began in astrophysics and software led to one of the most promising breakthroughs in oncology today—built on science, curiosity, and a partnership that began at home.
From the Stars to the Cell
Paul’s story defies convention. After earning degrees from MIT and Berkeley, he spent years in astrophysics at Harvard, before launching two successful software startups during the dot-com era. Then, a personal passion for health led him to co-author Perfect Health Diet and open a wellness retreat that helped thousands transform their lives.
“Once I learned how to be healthy,” he said, “I felt I had a duty to share it.”
But his greatest pivot came when his wife, a Harvard biomedical scientist, made a groundbreaking discovery in cancer biology—a discovery so profound it inspired Paul to found Angiex in 2015.
“I told her that if she ever discovered a way to cure cancer, I’d start a company to make it real,” he recalled. “And she did.”
Seed-funded by Peter Thiel, Angiex began developing AGX-101—an experimental therapy designed to selectively target and destroy tumor cells through a unique transport pathway discovered in his wife’s lab.
Engineering a Smarter Cancer Drug
Traditional chemotherapy is a blunt instrument, attacking both cancerous and healthy cells. AGX-101, however, works with surgical precision.
Paul explained that his wife’s research uncovered a fundamental transport route used by cells to move proteins from the surface to the nucleus—a process hijacked by cancer during tumor growth.
“This pathway is turned off in healthy adults,” Paul said, “but cancer switches it back on.”
By creating an antibody drug conjugate that can “hitchhike” along this pathway, Angiex found a way to deliver therapy directly into the nucleus of tumor cells—killing them from the inside out while sparing surrounding tissue.
“A majority of the injected drug goes to tumors,” Paul shared. “We’re seeing real tumor shrinkage with minimal off-target toxicity.”
The Long Road to a Breakthrough
Developing AGX-101 has been a marathon, not a sprint—nearly 15 years of research and refinement, built on earlier collaborations with Pfizer and countless preclinical experiments.
“We improved the therapeutic index tenfold compared to Pfizer’s baseline,” Paul said. “That means a wider margin between an effective and a safe dose—something almost unheard of in oncology.”
He credits this progress to scientific integrity and a refusal to cut corners.
“There’s a lot of mediocre science out there,” he said. “But when you can reproduce your results again and again, that’s when you know you’ve discovered something true.”
Balancing Global Consistency with Local Agility
With production facilities in Denmark and Ohio, Hamlet Protein optimizes its global supply chain to stay resilient amid tariffs, logistics challenges, and shifting energy costs.
The result: consistent quality worldwide—with flexibility to adjust for local efficiencies and sustainability requirements.
That flexibility also helps the company meet new environmental regulations, such as Europe’s Deforestation-Free Supply Chain (EUDR), without losing competitiveness. “We support sustainability,” Erik says, “but we have to move smartly to avoid pricing customers out of the market.”
Funding Through Trust
Unlike most biotech startups, Angiex raised its early funding not from venture capital but from people who had experienced Paul’s earlier work in health and wellness.
“Guests from our health retreat invested about $20 million,” he said. “They believed in the mission and the people behind it.”
That community-driven model allowed Angiex to grow without the short-term pressures of traditional investors—a rare advantage in an industry where drug development can take over a decade.
Toward a Universal Cancer Therapy
While still in early-stage trials, AGX-101’s biology suggests it could one day help nearly all solid tumor patients. The drug attacks cancer on multiple fronts:
-
Starving tumors by eliminating their blood supply.
-
Killing invasive cells capable of metastasis.
-
Activating the immune system to finish the job.
“We think of it as turning cancer from malignant to benign,” Paul said. “A tumor might still exist—but it can’t harm you.”
The company’s first focus is angiosarcoma, a rare and aggressive cancer of the blood vessels with no approved therapies. Success there could open the door to treating more common cancers, including glioblastoma, pancreatic, and liver tumors.
Patient-First Innovation
Angiex’s philosophy is simple: move carefully, test rigorously, and always put patients first.
“In our trials, we’ve seen significant tumor activity without off-tumor toxicities,” Paul said. “That’s the kind of data that gives you faith you’re on the right path.”
Working closely with world-class manufacturing partners and the FDA, Paul’s team is ensuring AGX-101’s scalability and stability meet the highest standards.
“It takes collaboration and humility,” he said. “You can’t do this alone.”
A Vision Beyond the Lab
For Paul, Angiex isn’t just a company—it’s a mission that fuses scientific rigor with human hope.
“We’re trying to save lives,” he said. “That’s what keeps you going through the 15-year grind.”
His advice for entrepreneurs entering biotech? Find people who share your purpose—and the patience to see it through.
“In this field, you need faith,” Paul said. “Faith in the science, in your team, and in the idea that good work eventually finds its way to the world.”
Listen to the full episode.
Interested in being featured on the podcast? Reach out to podcast@industryignited.com
